Neoadjuvant Anti-PD-L1 (Durvalumab/MEDI4736) Plus Anti-CTLA-4 (Tremelimumab) and Radiation for High Risk Soft-Tissue Sarcoma

Trial Profile

Neoadjuvant Anti-PD-L1 (Durvalumab/MEDI4736) Plus Anti-CTLA-4 (Tremelimumab) and Radiation for High Risk Soft-Tissue Sarcoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NEXIS
  • Most Recent Events

    • 21 Jun 2017 Planned End Date changed from 1 May 2022 to 1 Jun 2022.
    • 21 Jun 2017 Planned primary completion date changed from 1 May 2020 to 1 Jun 2020.
    • 21 Jun 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top